title: Cellular events during arthritis-induced hyperalgesia are mediated by interleukin-6 and p38 MAPK and their effects on the expression of spinal mu-opioid receptors.
abstract: Activation of mitogen-activated protein kinase (MAPK) enzymes in nociceptive plasticity has been extensively studied. P38 MAPK enzyme, which can be activated by cytokines, acts as a crucial intracellular regulator of environmental changes. The aim of this study was to elucidate the cellular events during arthritis-induced hyperalgesia that are mediated by interleukin-6 and p38 MAPK, and their effects on the expression of spinal mu-opioid receptors (MORs), in different stages of arthritis in male Wistar rats. Complete Freund's adjuvant (CFA)-induced arthritis (AA) was caused by subcutaneous injection of CFA into the rats' hindpaw. Anti-IL-6 antibody and p38 MAPK phosphorylation inhibitor were administered during 21 days of study. Spinal MOR, p38, and phosphorylated-p38 (pp38) proteins expressions were detected by Western blotting. Daily treatment with anti-IL-6 antibody and p38 MAPK phosphorylation inhibitor, SB203580, significantly decreased paw edema in AA group. Daily anti-IL-6 and SB203580 administration caused a significant reduction in hyperalgesia in the first week of the study, but increased hyperalgesia in the next 2 weeks in experimental groups compared to the AA control group. Expression of pp38 MAPK protein significantly decreased on the 3, 7, 14, and 21 days in AA+SB203580 and AA+anti-IL6 groups compared to AA group. Additionally, daily treatment with anti-IL6 antibody and SB203580 in AA group caused significantly decrease in spinal MOR expression compared to AA control group. The results of our study can confirm that activated spinal p38 MAPK enzyme may play an important role in cellular IL-6 signaling pathways in hyperalgesia variation during different stages of AA inflammation. Also, it can be suggested that at least a part of p38 MAPK effects on hyperalgesia is mediated by spinal MOR expression variation.
authors.affiliation: Physiology Department, Neuroscience Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran. jzaringhalam@yahoo.com
authors.forename: Jalal
authors.initials: J
authors.lastname: Zaringhalam
authors.forename: Elaheh
authors.initials: E
authors.lastname: Tekieh
authors.forename: Homa
authors.initials: H
authors.lastname: Manaheji
authors.forename: Zeinab
authors.initials: Z
authors.lastname: Akhtari
mesh_terms: D000818:Animals; D001169:Arthritis, Experimental / Q000503:physiopathology*; D006930:Hyperalgesia / Q000209:etiology*; D007093:Imidazoles / Q000494:pharmacology; D015850:Interleukin-6 / Q000097:blood / Q000502:physiology*; D008297:Male; D010766:Phosphorylation; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D017450:Receptors, Opioid, mu / Q000032:analysis / Q000502:physiology*; D013116:Spinal Cord / Q000737:chemistry*; D048051:p38 Mitogen-Activated Protein Kinases / Q000502:physiology*
chemical_list: D007093:Imidazoles; D015850:Interleukin-6; D011725:Pyridines; D017450:Receptors, Opioid, mu; D048051:p38 Mitogen-Activated Protein Kinases; C093642:SB 203580